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Abstract hUBC9, an E2 ubiquitin conjugating enzyme, was
identified by yeast two-hybrid screening and coprecipitation
studies to interact with MEKK1 and the type I TNF-K receptor,
respectively. Because both of these proteins regulate NFUB
activity, the role of hUBC9 in modulating NFUB activity was
investigated. Overexpression of hUBC9 in HeLa cells stimulated
the activity of NFUB as determined by NFUB reporter and IL-6
secretion assays. hUBC9 also synergized with MEKK1 to
activate NFUB reporter activity. Thus, hUBC9 modulates NFUB
activity which, at least in part, can be attributed to its interaction
with MEKK1 and the type I TNF-K receptor.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
One mechanism by which the levels of certain proteins are
regulated in the cell is through their ubiquination and subse-
quent degradation by proteosomes (as reviewed in [1^3]). The
process by which proteins are ubiquinated involves the coor-
dinated activity of three families of enzymes, designated E1,
E2, and E3. Ten di¡erent E2 enzymes have been identi¢ed in
yeast (designated ubiquitin conjugating enzyme, or UBC1^
UBC10) [1]. UBC9 has been found to be an essential gene
for cell cycle progression [4] and is involved in the degradation
of S and M phase cyclins in yeast [4]. In addition, mammalian
homologues of UBC9 have been found to interact with a
variety of proteins, including ETS-1 [5], c-Jun [6], glucocorti-
coid receptor [6], RanBP2 [7], and Rad51 recombination pro-
tein [8]. The signi¢cance for most of these interactions, how-
ever, is unknown.
Recently it has been shown that UBC9 may be an E2 en-
zyme not for ubiquitin, but for the ubiquitin-like protein
SMT3p [9^11]. The mammalian homologue of SMT3p,
SUMO-1 (also known as sentrin [10]), has been found to be
conjugated to Ran-GTPase activating protein RanGAP1 [12].
This conjugation has been shown to be necessary for the as-
sociation of RanGAP1 to Ran-GTP binding protein RanBP2
at the nuclear pore complex [12].
We report on the identi¢cation of two additional proteins
which interact with the human homologue of UBC9
(hUBC9), the type I tumor necrosis factor-K (TNF-K) recep-
tor and MEKK1. The type I TNF-K receptor is a 55 kDa
protein which is associated with a variety of functions when
activated, including apoptosis, NFUB activation, and Jun N-
terminal kinase activation [13,14]. The induction of both
NFUB activity and apoptosis by type I TNF-K receptor is
mediated through its intracellular ‘death domain’ region
[14,15]. In the TNF-K mediated activation of NFUB, a path-
way is stimulated in which the last step is the phosphorylation
dependent degradation of IUB by proteosomes [16^19].
MEKK1 is a kinase which stimulates the stress activated
protein kinase pathway [20,21]. It has been shown to phos-
phorylate SEK1, a stress kinase protein (SAPK) activator,
which in turn phosphorylates and activates SAPK/JNK [22].
MEKK1 has also been shown to activate NFUB activity when
overexpressed in cells [23^25]. The mechanism by which
MEKK1 induces NFUB activity, however, is unclear.
Thus, because of the association of the type I TNF-K re-
ceptor and MEKK1 with NFUB activation, we also deter-
mined whether hUBC9 modulated TNF-K induced NFUB ac-
tivity. In this report we show that hUBC9 overexpression
induces NFUB activity and can synergize with MEKK1 for
stimulating this activity.
2. Materials and methods
2.1. Cell culture
HeLa cells were obtained from ATCC (Rockville, MD). HeLa cells
were grown in minimal essential medium with Earle’s salts supple-
mented with 5% fetal bovine serum, 2 mM L-glutamine, 100 U/ml
penicillin G, and 100 U/ml streptomycin sulfate. Cells were grown
at 37‡C with 95% humidity and 5% CO2. All cell culture reagents
were purchased from Gibco-BRL (Gaithersburg, MD).
2.2. Yeast two-hybrid screening and binding studies
Screening was performed using standard yeast two-hybrid method-
ology [26^28]. A human Jurkat T cell cDNA library (2.5U106 indi-
vidual recombinants) in the vector pPC86 [29] was screened using as
bait the cytoplasmic domain of the human type I TNF-K receptor
[30,31], obtained by reverse transcriptase-polymerase chain reaction
(RT-PCR) and cloned into pPC97 [29]. The library and bait were
cotransformed into the yeast two-hybrid strain Y190 (MATa, ura3-
52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3,112, gal4D, gal80D,
cyhr2, LYS2: :GAL1uas-HIS3tata-HIS3, URA3: :GAL1uas-GAL1tata-
lacZ) using a standard lithium acetate-polyethylene glycol method
[32]. A total of 2U106 clones were screened. Positive library clones
(growth on His3 medium, and LacZ reporter activity) were rescued,
veri¢ed, and subjected to DNA sequencing.
For domain mapping, type I TNF-K receptor bait plasmids con-
taining the death domain (nucleotides 1321^1579) or the cytoplasmic
region from the transmembrane to the death domain (nucleotides
958^1320) were prepared by PCR, subcloned into pPC97 and ana-
lyzed as described above.
A plasmid containing the murine MEKK1 [20], pECE-MEKK1
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(gift of Dr. Jacques PouysseŁgur, UniversiteŁ de Nice, Nice, France) was
used to transfer the MEKK1 coding sequence to the two-hybrid DNA
binding domain vector pGBT9 (Clontech, Palo Alto, CA). This plas-
mid was used to screen a HeLa cell cDNA library in pGAD-GH
(Clontech) in the yeast strain yCM17 (MATa, ura3, trp1, leu2, his3,
lys2, ade2, gal4, gal80, met16: :URA3-GAL1-10LacZ). Positive clones
were treated as described above.
hUBC9 binding domain mapping of MEKK1 was accomplished by
cloning fragments of the MEKK1 cDNA corresponding to the regu-
latory (amino acids 1^369) and kinase domains (amino acids 363^
673), as well as a fragment encoding amino acids 284^673 into
pGBT9. These constructs were cotransformed with the hUBC9 acti-
vation domain plasmid obtained from the yeast two-hybrid screen, as
described above, and scored for interaction.
2.3. Glutathione S-transferase (GST)-hUBC9 precipitation analysis
hUBC9 cDNA was cloned into pGEX2T (Pharmacia Biotech, Pis-
cataway, NJ). The resulting 45 kDa GST-hUBC9 fusion protein pro-
duced was puri¢ed by glutathione-Sepharose chromatography [33].
Coupled transcription/translation (TNT-Quick; Promega, Madison,
WI) was performed on DNA templates with a T7 promoter upstream
of the appropriate gene fragment containing an in-frame Kozak trans-
lation initiation sequence [34], using [35S]methionine (Amersham, Ar-
lington Heights, IL) as a label. Precipitation reactions were prepared
using either 5 Wg of hUBC9-GST or GST for each reaction, prebound
to glutathione-Sepharose. The prebound hUBC9-GST and GST, re-
spectively, were blocked in 200 Wl of 20 mM Tris, pH 7.5, 150 mM
NaCl, 0.1% Tween 20, and 2% bovine serum albumin for 1 h at 4‡C.
After this incubation, 25 Wl of the respective type I TNF-K receptor or
MEKK1 35S-labeled transcription/translation products was added.
The precipitation reactions were incubated for 2 h further at 4‡C
with gentle mixing. The resin containing bound proteins was then
pelleted followed by extensive washing (3U) with 20 mM Tris, pH
7.5, 150 mM NaCl, and 0.1% Tween 20, with pelleting after each
wash. The resin was then resuspended in SDS-polyacrylamide gel
loading dye and boiled for 5 min, followed by electrophoresis on 4^
20% precast Tris-glycine polyacrylamide gels (Novex, San Diego,
CA). After electrophoresis, the gels were ¢xed in acetic acid/methanol
for 30 min, followed by a 30 min incubation in enhancing reagent
(Amplify, Amersham). The gels were then vacuum dried onto ¢lter
paper and autoradiographed for 24 h.
2.4. Plasmid constructs
The NFUB reporter construct, (IgU)3-conaluc, which contains three
copies of the immunoglobulin U chain enhancer UB site upstream of
the minimal conalbumin promoter [35], was a generous gift from Dr.
Alain Israeºl (Institut Pasteur, Paris, France).
hUBC9 [8], hUBC5 [36], and IUB [37] constructs for mammalian
cell expression (designated with pC pre¢x; e.g. pC-hUBC9) utilized
the pCDNA 3.1 vector (Invitrogen, Carlsbad, CA) with a hemagluta-
nin tag at the NH2-terminus. The catalytic domain construct of mur-
ine MEKK1 used for mammalian cell expression, HA-vMAPKKK in
pECE [38] (designated in this paper as pC-MEKK1CAT), was a gift
of Dr. Jacques PouysseŁgur (UniversiteŁ de Nice) and contained a he-
maglutanin tag at the NH2-terminus of the catalytic domain of the
kinase [20].
2.5. Mutagenesis
The mutagenesis of hUBC9 was performed using the Transformer
site directed mutagenesis kit (Clontech) and the mutagenesis oligo
5P-CTTCGGGGACAGTGTCCCTGTCCATCTTAGAGG-3P. The
underlined sequence corresponds to the Cys (TGC) to Ser (TCC)
codon change. The presence of the mutation was con¢rmed by
DNA sequencing. DNA sequencing was performed using an ABI
PRISM dye terminator cycle sequencing kit (Perkin Elmer, Foster
City, CA) following the protocol described by the manufacturer. Au-
tomative DNA sequence analysis was performed using a 3T3 DNA
sequencer (Applied Biosystems).
2.6. Transfection studies
HeLa cell transfections were performed in 6 well dishes using a
calcium phosphate transfection kit (Gibco-BRL) following the proto-
col described by the manufacturer. Transfection medium was re-
placed, 24 h following the transfection, with complete medium, fol-
lowed 8 h later by placing the cells in serum free medium. After a 16 h
incubation in serum free medium, medium was changed to complete
medium which, when indicated, contained 100 ng/ml TNF-K (Gibco-
BRL). 24 h after treatment, cells were harvested for measurement of
luciferase. Luciferase assays were performed using a luciferase assay
system (Promega) according to the manufacturer’s instructions. Lu-
minescence was measured using an ICN Titertek Luminoskan (Lab-
systems, Needham Heights, MA). In experiments in which expression
vector constructs were transfected, expression of the respective pro-
teins was con¢rmed by Western analysis [39], using a hemaglutanin
speci¢c antibody (BAbCO, Richmond, CA).
2.7. Interleukin 6 (IL-6) ELISA assays
For IL-6 measurements, a 200 Wl aliquot of medium (total volume
2 ml) was analyzed for each experimental sample. IL-6 levels were
quantitated using a Duoset IL-6 ELISA kit (Genzyme, Cambridge,
MA) using the protocol supplied by the manufacturer. ELISA meas-
urements were obtained using an EL 312e microtiter plate reader
(Bio-Tek Instruments, Winooski, VT).
3. Results
3.1. hUBC9 interacts with type I TNF-K receptor and MEKK1
Two separate yeast two-hybrid screens were performed to
identify binding partners for the human type I TNF-K recep-
tor and MEKK1, respectively. For the type I TNF-K receptor,
the cytoplasmic domain of the receptor was used as bait to
screen a human Jurkat cDNA library. In the MEKK1 screen-
ing, the murine clone was used to screen a HeLa cell cDNA
library. Both screens isolated hUBC9 as a binding partner for
their respective bait. The interaction was con¢rmed by the
reintroduction of clones for hUBC9 into yeast with their re-
spective bait (Fig. 1).
As an additional con¢rmation of the interaction of hUBC9
with these proteins, it was determined if the transcribed/trans-
lated product of the respective protein could interact with
GST-hUBC9. Both 35S-labeled type I TNF-K receptor and
MEKK1 were found to bind to GST-hUBC9 (Fig. 2A), but
not GST alone (Fig. 2B).
3.2. hUBC9 binds to the catalytic domain of MEKK1 and the
death domain of type 1 TNF-K receptor
Deletion mutants of MEKK1 and the type I TNF-K recep-
tor, respectively, were characterized for their ability to interact
with hUBC-9, using the yeast two-hybrid system (Fig. 1) and
GST-hUBC9 pull down experiments (Fig. 2). For MEKK1 it
was determined that the catalytic domain interacted with
hUBC9. For the type I TNF-K receptor, it was found that
hUBC9 interacts with the ‘death domain’ of the molecule.
3.3. hUBC9 induces NFUB activity
Because the activation of MEKK1 and type I TNF-K re-
ceptor has been associated with the activation of NFUB, ex-
periments were performed to determine if hUBC9 can modu-
late NFUB activity. When hUBC9 was overexpressed in HeLa
cells cotransfected with an NFUB-luciferase reporter con-
struct, an increase in basal and TNF-K induced luciferase
activity was observed over control transfected samples (Fig.
3a). Coexpression of IUB with hUBC9 completely inhibited
both hUBC9 stimulated and TNF-K induced NFUB reporter
activity, indicating that the induction of reporter activity was
due to NFUB activation (Fig. 3a). Other reporter constructs
tested (e.g. heat shock and serum response) were not stimu-
lated by hUBC9 (data not shown), indicating that the e¡ects
seen with hUBC9 were speci¢c for NFUB.
In order to further con¢rm that the overexpression of
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hUBC9 induces NFUB activity, NFUB stimulation of IL-6
secretion was tested. When HeLa cells overexpressing
hUBC9 were treated with TNF-K, a signi¢cant increase in
IL-6 secretion was observed, compared to vector alone trans-
fected cells (Fig. 3b).
3.4. Characterization of the induction of NFUB activity by
hUBC9
Studies were performed to determine if the induction of
NFUB activity by hUBC9 was a general feature of E2 en-
zymes. When hUBC5, an E2 enzyme associated with P53
degradation [36], was overexpressed in HeLa cells no stimu-
lation of TNF-K induced NFUB activity was observed. (Fig.
4a). This ¢nding indicates that the stimulation of NFUB ac-
tivity by hUBC9 was not a general property of E2 enzymes.
To determine the importance of E2 enzymatic activity in
hUBC9’s ability to stimulate NFUB activity, HeLa cells
were transfected with a mutated form of hUBC9 in which a
conserved cysteine residue important for thiolester formation
[1] was mutated to serine (Cys93-Ser). As shown in Fig. 4b, the
Cys93-Ser mutant of hUBC9 was also able to stimulate TNF-
K induced NFUB reporter activity. The general conclusion
from these experiments is that the induction of NFUB activity
by hUBC9 is not due to its E2 enzymatic properties.
3.5. hUBC9 synergizes with MEKK1 to activate NFUB activity
Since it has been reported that MEKK1 can stimulate
NFUB activity [23,25], it was tested whether hUBC9, since it
can interact with MEKK1, can enhance the ability of
MEKK1 to induce NFUB activity. Transfection of the cata-
lytic domain of MEKK1 into HeLa cells gave a 100-fold
activation of TNF-K induced NFUB reporter activity (Fig.
5). Cotransfection of the catalytic domain of MEKK1 with
hUBC9 resulted in a 150-fold activation of TNF-K induced
NFUB reporter activity, indicating a synergistic e¡ect of the
two proteins on NFUB activity.
4. Discussion
In this report, we describe the interaction of the human
homologue of UBC9 with two proteins associated with the
induction of NFUB activation, MEKK1 and the type 1
TNFK receptor. In addition, we show that overexpression of
hUBC9 in HeLa cells results in the activation of NFUB activ-
ity.
UBC9 is a member of a family of ubiquitin conjugating
enzymes involved in the transfer of ubiquitin to cellular sub-
strates [1,2]. The transfer of ubiquitin to proteins has been
found to be an essential element in the process by which
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Fig. 1. Yeast two-hybrid binding analysis of the interaction of hUBC9 with the TNF-K receptor type I and MEKK1. Interaction experiments
were performed by using the portions of the TNF-R1 and MEKK1 indicated, as constructs in a two-hybrid GAL4 DNA binding domain vec-
tor (DB Constructs) cotransformed with hUBC9 in a GAL4 activation domain vector, as described in Section 2. Interactions are scored as a +
and no interaction as a 3.
Fig. 2. Interaction of 35S-labeled MEKK1 and TNF-K receptor with
GST-hUBC9. 35S-labeled translation products for (1) MEKK1, (2)
MEKK1 CAT, (3) death domain of type I TNF-K receptor, and (4)
cytoplasmic domain of type I TNF-K receptor with either (A) GST-
hUBC9 or (B) GST. 35S-labeled translation products which bound
to GST fusion proteins were analyzed by SDS-PAGE electrophore-
sis, as described in Section 2.
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such proteins are degraded by the proteosome. More recently,
hUBC9 has been shown to be an E2 enzyme for SUMO-1 [9^
11], a ubiquitin-like molecule that is crosslinked to proteins
associated with nuclear transport [12].
It would be interesting to speculate, especially with the ¢nd-
ings on SUMO-1, that the E2 enzymatic activities of hUBC9
are involved in its ability to stimulate NFUB activity. How-
ever, data presented in this report do not support this theory.
The NFUB stimulatory activity of hUBC9 cannot be inhibited
by mutating the Cys93 site of hUBC9 to Ser. The Cys93 site is
conserved amongst E2 enzymes and is necessary for thiolester
formation [1]. The ¢nding that the E2 enzyme defective mu-
tant of hUBC9 can still stimulate transcriptional activity is
similar to what was seen by Hahn et al. [5] on the activation
of ETS-1 transcriptional activity by hUBC9.
The implication of these results is that hUBC9 has addi-
tional properties which are not dependent on its E2 enzymatic
activity. Given the ¢ndings that this protein interacts with a
wide range of other proteins, one may speculate that it may
play a role as a sca¡olding protein. In the case of MEKK1,
hUBC9 may aid the ability of MEKK1 to phosphorylate giv-
en substrates by bringing MEKK1 and the given substrate
together. Such a model would be analogous to that proposed
for the MAP kinase cascade which is associated with the
pheromone-response pathway in yeast [40]. In this model,
Ste5 acts as a sca¡old to bring the MAP kinase components
Ste11, Ste7, and Fus3p together to promote the formation of
a kinase complex.
Recently, Tashiro et al. [41] showed that the mouse homo-
logue of UBC9 interacts with IUB. They found that the over-
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Fig. 4. E¡ect of hUBC5 or Cys93-Ser mutation of hUBC9 on NFUB activation. a: HeLa cells were cotransfected with NFUB reporter and ei-
ther pC-hUBC9, pC-hUBC5, or pCDNA 3.1 (1:1 ratio) and then either untreated or treated with 100 ng/ml TNF-K 48 h later. Cells were then
analyzed 24 h later for luciferase activity. b: HeLa cells were cotransfected with NFUB reporter and either pC-C93-S hUBC9, pC-hUBC9, or
pCDNA 3.1 (1:1 ratio) and analyzed, as described above, for the stimulation of NFUB activation. Results are representative of duplicate deter-
minations þ S.E.M.
Fig. 3. Activation of NFUB activity by hUBC9. a: HeLa cells were cotransfected with NFUB reporter construct and either pC-hUBC9 and
pCDNA 3.1 (2:1:1 ratio), pC-hUBC9 and pC-IUB (2:1:1 ratio), or pCDNA 3.1 (1:1 ratio). After 48 h, cells were untreated or treated with
100 ng/ml TNF-K. Cells were then analyzed, 24 h later, for luciferase activity as described in Section 2. b: HeLa cells were cotransfected with
NFUB reporter construct and either pC-hUBC9 or pCDNA 3.1 (1:1 ratio). Cells, 48 h after transfection, were either untreated or treated with
TNF-K (100 ng/ml). After an additional 24 h medium was analyzed for IL-6 secretion, as described in Section 2. Data are representative of
three separate experiments þ S.E.M.
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expression of an E2 defective mutant of mouse UBC9 delayed
the TNF-K induced degradation of IUB and induction of
NFUB DNA binding activity produced within the ¢rst 11
min of treatment. However, in our studies, where measure-
ments were not taken until at least 2.5 h following TNF-K
treatment, an E2 defective mutant of hUBC9 induced NFUB
activity. In summary, these results infer a complex role of
hUBC9 in the regulation of NFUB activity whereby its E2
activity may be important in the initial stimulation of
NFUB, but other properties of this protein, such as sca¡old-
ing, may be important in later stages.
In conclusion, we have identi¢ed hUBC9 as a protein which
is involved in the regulation of NFUB activity. The ability of
hUBC9 to stimulate NFUB activity does not appear to be due
to its enzymatic properties, but potentially through its ability
to associate with proteins which are involved in the activation
of NFUB, such as MEKK1 and type I TNF-K receptor. The
understanding of the mechanism by which this activation oc-
curs will provide additional insight into the regulation of
NFUB activity and hUBC9 function.
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Fig. 5. hUBC9 synergizes with MEKK1 to stimulate NFUB activity.
HeLa cells were cotransfected with NFUB reporter and either pC-
MEKK1CAT and pCDNA 3.1 (2:1:1 ratio), pC-hUBC9 and
pCDNA 3.1 (2:1:1: ratio), pC-MEKK1CAT and pC-hUBC9 (2:1:1
ratio), or pCDNA (1:1 ratio). Cells, 48 h after transfection, were ei-
ther untreated or treated with 100 ng/ml TNF-K, and then proc-
essed 24 h later for luciferase activity. Data are representative of
duplicate experiments þ S.E.M.
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